Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.
复制标题
DOI：
10.4161/onci.1.1.18344
复制
发表时间：
2012-01-01
期刊：
影响因子：
7.2
通讯作者：
Butterfield LH
中科院分区：
文献类型：
--
作者：
Pardee AD;Butterfield LH
目前治疗晚期肝细胞癌的方法是微效的，并且会加重潜在的肝病。免疫疗法能够诱导无毒、系统、持久的抗肿瘤活性，这使得它特别适合用于肝细胞癌的治疗。虽然在早期临床试验中已经获得了治疗益处，但基于免疫的疗法的疗效受到肝癌几个独特特性的限制，最显著的是在健康和患病(慢性感染或携带肿瘤)状态下肝脏固有的耐受性。既能对抗这些免疫抑制机制又能增强肿瘤特异性免疫的治疗方案有望显著改善肝细胞癌患者的临床预后。
Current therapies for advanced hepatocellular carcinoma (HCC) are marginally effective and exacerbate underlying liver disease. The ability of immunotherapy to elicit nontoxic, systemic, long-lived anti-tumor activity makes it particularly well-suited for use in the setting of HCC. While therapeutic benefit has been achieved in early clinical trials, the efficacy of immune-based therapies is limited by several unique properties of HCC, most notably the inherently tolerogenic character of the liver in both healthy and diseased (chronically-infected or tumor-bearing) states. Therapeutic regimens that both counteract these immunosuppressive mechanisms and amplify tumor-specific immunity are expected to profoundly improve clinical outcomes for HCC patients.
登录
查看更多内容
影响因子：
15.3
作者：
Das, Abhishek;Hoare, Matthew;Davies, Nathan;Lopes, A. Ross;Dunn, Claire;Kennedy, Patrick T. F.;Alexander, Graeme;Finney, Helene;Lawson, Alistair;Plunkett, Fiona J.;Bertoletti, Antonio;Akbar, Arne N.;Maini, Mala K.
通讯作者：
Maini, Mala K.
影响因子：
20.3
作者：
Hinrichs, Christian S.;Borman, Zachary A.;Restifo, Nicholas P.
通讯作者：
Restifo, Nicholas P.
影响因子：
15.9
作者：
Bowen, DG;Zen, M;Bertolino, P
通讯作者：
Bertolino, P
影响因子：
5.8
作者：
Butterfield, Lisa H.;Ribas, Antoni;Economou, James S.
通讯作者：
Economou, James S.
影响因子：
4.4
作者：
Garbi, N;Arnold, B;Ganss, R
通讯作者：
Ganss, R